Andrx, Glaxo In New Row Over Wellbutrin
The complaint, filed in the U.S. District Court for the Southern District of Florida, also names Glaxo subsidiary SmithKline Beecham Corp. It points to the defendant’s extended-release, 150 mg doses as the source of infringement.
Andrx applied for the patent in the case in May 2003, and it was issued in June 2005. It covers...
To view the full article, register now.